Arnold Bloch Leibler has advised Hexima Limited on its successful ASX listing. Hexima is a clinical stage biotechnology company developing a new prescription treatment for onychomycosis…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
